<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907697</url>
  </required_header>
  <id_info>
    <org_study_id>K23DA039037</org_study_id>
    <nct_id>NCT02907697</nct_id>
  </id_info>
  <brief_title>Adherence Intervention for HIV-infected Drug Users</brief_title>
  <official_title>Adherence Intervention for HIV-infected Drug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many people living with HIV use illicit drugs, which leads to worsened health outcomes and
      increased transmission of HIV due to poor adherence to medication regimens. This research
      will develop an intervention targeting medication adherence that is tailored to the unique
      needs of HIV-infected drug users. This research will promote adherence and improve treatment
      outcomes among HIV-infected drug users thereby minimizing the development of drug resistant
      strains of HIV and reducing transmission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This K23 research and training award advances the long-term goal of improving treatment
      outcomes and reducing transmission of HIV among HIV-infected drug users. The proposed
      training and research plans will enable the PI to develop the skills needed for an
      independent research career in the area of illicit drug use and HIV adherence intervention.
      The objective of this award is to develop skills in implementation science, behavioral
      intervention development and evaluation with drug using populations, and in-depth qualitative
      data analysis to accelerate refinement and effective implementation of interventions for
      HIV-infected drug users. Multiple comorbidities such as drug use and HIV act synergistically
      to produce poorer health outcomes and increase morbidity, mortality, and transmission of HIV.
      Consequently, effective and sustainable interventions adapted to drug users to improve
      antiretroviral medication adherence and reduce risk behaviors are urgently needed. Drug users
      present unique treatment challenges compared with other HIV-infected populations, including
      lower rates of adherence and inferior treatment outcomes. Additionally, interpersonal
      factors, including social support, negative patient-provider interactions, and socioeconomic
      challenges present significant barriers to adherence. Thus, the generalizability of current
      adherence interventions to drug users is limited, and there is a pressing need for
      efficacious interventions adapted to HIV-infected drug using populations. This project
      addresses this gap by being the first to adapt and test the acceptability and efficacy of a
      combined adherence and brief motivational intervention for HIV-infected drug users.
      Specifically, the intervention will augment the established Life Steps adherence intervention
      to include: (1) a tailored Life Steps module addressing the unique needs of illicit drug
      users, aimed at improving medication adherence; (2) a brief Motivational Interview to address
      drug use and other risk behaviors; and (3) two follow-up booster sessions. A three-phase,
      top-down research approach to adapt, refine, and pilot test the intervention will be
      conducted. Phase 1 will include focus groups with HIV-infected drug users currently
      prescribed antiretroviral medications and individual interviews with community-based
      clinicians. Phase 2 will include manual development, therapist training, a pilot trial,
      in-depth qualitative interviews, and further manual revisions. Phase 3 will include a small,
      2-armed (intervention vs. health education control) randomized controlled trial with 60
      HIV-infected drug users. Feasibility, acceptability, and preliminary indication of
      improvement in antiretroviral adherence and reduction in drug use will be examined at 1-, 3-,
      and 6-month follow-ups. To enable the PI to pursue this long-term research agenda, she will
      work with experienced mentors to build three areas of expertise: (1) proficiency in
      qualitative research methods and analysis; (2) skills in intervention development and
      evaluation with illicit drug using populations; (3) expertise in advanced longitudinal data
      analysis; and (4) implementation science. This K23 study addresses a key priority in HIV
      treatment science, and it will fully prepare the PI for an independent research career as an
      HIV intervention scientist.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antiretroviral Adherence</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>Change in Antiretroviral Adherence will be assessed by use of medical event monitoring systems (MEMS). MEMS is a pill-bottle-cap with a pressure activated chip which records time/date the bottle is opened. MEMS data will be collected on one antiretroviral medication following a triage criterion established in studies of antiretroviral adherence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Center for Epidemiologic Studies Depression Scale (CES-D)</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>Change in depression over time will be assessed using the Center for Epidemiologic Studies Depression Scale (CES-D) is a widely used 20-item measure and has good sensitivity and specificity and high internal consistency and has been used extensively with PLWH and is related to ART adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Treatment Adherence Self-Efficacy (HIV-ASES)</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>Change in treatment self-efficacy will be assessed using the HIV-ASES whic is a 12-item scale of patient confidence in their ability to carry out behaviors related to adhering to medication regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>U.S. Health Resources and Service Administration measure of HIV treatment retention</measure>
    <time_frame>1-, 6-months</time_frame>
    <description>Change in HIV Treatment Retention will be measured with the U.S. Health Resources and Service Administration measure of HIV treatment retention, which defines treatment retention as having at least two outpatient visits separated by at least 90 days during a 12-month period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Assessment Battery</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>Change in HIV risk behavior will be assessed using the Risk Assessment Battery which assesses HIV risk behavior, including sex risk and drug risk, in the past six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV1 Ultra RT PCR-Roche test</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>This lab assay will be used to assess change in HIV viral load over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Toxicology Screens</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>Participants will be asked to give a urine sample at each assessment. Redwood Toxicology Redi-cups urine drug screens have test strips in the specimen lids allowing for fast screening without spillage. The Redi-cups 5-panel urine drug screen tests for cocaine, THC, methamphetamines, opiates, and benzodiazepines. This will provide biological verification of drug use to assess change in drug use over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACTG Self-Reported Antiretroviral Medication Adherence</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>The ACTG scale will be used to assess self-reported adherence to antiretroviral medications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Timeline Followback (TLFB)</measure>
    <time_frame>1-, 3-, and 6-months</time_frame>
    <description>The TLFB will be used to assess change in alcohol, tobacco, and illicit drugs over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>HIV</condition>
  <condition>Substance Use</condition>
  <arm_group>
    <arm_group_label>LifeSteps-Drug Use</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Life Steps-Drug Use</intervention_name>
    <arm_group_label>LifeSteps-Drug Use</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>General Health Education</intervention_name>
    <arm_group_label>Health Education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  over 18 years of age

          -  HIV-infected

          -  prescribed an antiretroviral regimen

          -  meet DSM-V criteria for a substance use disorder (other than tobacco and alcohol) and
             report â‰¥3 days of use of an illicit drug per month over the past 90 days.

          -  self-report &lt;100% adherence and have experienced a detectable viral load (&gt;20
             copies/mL) within the last 6 months.

        Exclusion Criteria:

          -  cognitive impairments that jeopardize informed consent

          -  active psychosis

          -  current suicidal ideation

          -  not fluent in English

          -  have a prescription for and report only medicinal use of marijuana
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kasey Claborn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>adherence</keyword>
  <keyword>substance use</keyword>
  <keyword>HIV care continuum</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

